Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 25, Issue 2, 1997, Pages 209-233

  Rosner, Gary L ^a   Müller, Peter ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Bayesian analysis; Dirichlet process; Kernel density estimation; Mixture models; Nonparametric regression

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

BAYES THEOREM; BONE MARROW DEPRESSION; CANCER; COMPUTER SIMULATION; HUMAN; MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW;

EID: 0030683646     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025784113869     Document Type: Review

References (44)

1. L. B. Sheiner, S. Beal, B. Rosenberg, and V. V. Marathe. Forecasting individual pharmacokinetics. Clin Pharmacol. Ther. 26:294-305 (1979).
2. A. Iliadis, M. Bachir-Raho, R. Bruno, and R. Favre. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions. J. Pharmacokin. Biopharm. 13:101-115 (1985).
3. A. K. Hurst, M. A. Yoshinaga, G. H. Mitani, K. A. Foo, R. W. Jelliffe, and E. C. Harrison. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob. Agents Chemother. 34:1165-1171 (1990).
4. R. W. Jelliffe, A. Schumitzky, M. V. Guilder, M. Liu, L. Hu, P. Maire, P. Gomis, X. Barbaut, and B. Tahani. Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit. 15:380-393 (1993).
5. J. Wakefield. The Bayesian analysis of population pharmacokinetic models. J. Am. Statist. Assoc. 91:62-75 (1996).
6. J.-L. Steimer, A. Mallet, and F. Mentré. Estimating interindividual pharmacokinetic variability. In M. Rowland, J.-L. Steimer, and L. Sheiner (eds.), Variability in Drug Therapy: Description, Estimation, and Control, Raven Press, New York, 1985, pp. 65-111.
7. L. B. Sheiner and T. H. Grasela, Jr. An introduction to mixed effect modeling: Concepts, definitions, and justification. J. Pharmacokin. Biopharm. 19 (Suppl.):11s-24s (1991).
8. S. L. Beal and L. B. Sheiner. Estimating population kinetics. CRC Crit. Rev. Biomed. Eng. 8:195-222 (1982).
9. A. Mallet, F. Mentré, J.-L. Steimer, and F. Lokiec. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J. Pharmacokin Biopharm. 16:311-327 (1988).
10. A. Mallet, F. Mentré, J. Gilles, A. W. Kelman, A. H. Thomson, S. M. Bryson, and B. Whiting. Handling covariates in population pharmacokinetics, with an application to Gentamicin. Biomed. Meas. Inform. Contr. 2:138-146 (1988).
11. M. Jerling, Y. Merle, F. Mentré, and A. Mallet. Population pharmacokinetics of nortryptline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 - an evaluation with the nonparametric maximum likelihood method. Br. J. Clin. Pharmacol. 38:453-462 (1994).
12. F. Mentré and A. Mallet. Handling covariates in population pharmacokinetics. Int. J. Biomed. Comput. 36:25-33 (1994).
13. M. Davidian and A. R. Gallant. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. J. Pharmacokin. Biopharm. 20:529-556 (1992).
14. M. Davidian and A. R. Gallant. The nonlinear mixed effects model with a smooth random effects density. Biometrika 80:475-488 (1993).
15. P. O. Maitre, M. Bührer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayesian regression and NONMEM population analysis: Application to midazolam. J. Pharmacokin. Biopharm. 19:377-384 (1991).
16. M. D. Escobar and M. West. Bayesian density estimation and inference using mixtures. J. Am. Statist. Assoc. 90:577-588 (1995).
17. P. Müller and G. L. Rosner. A Bayesian population model with hierarchical mixture priors applied to blood count data. J. Am. Statist. Assoc. (in press).
18. T. S. Ferguson. A Bayesian analysis of some nonparametric problems. Ann. Statist. 1:209- 230 (1973).
19. T. S. Ferguson. Bayesian density estimation by mixtures of normal distributions. In H. Rizvi and J. Rustagi (eds.), Recent Advances in Statistics. Academic Press, New York, 1983, pp. 287-302.
20. A. O'Hagan. Kendall's Advanced Theory of Statistics, Vol. 2B: Bayesian Inference, Halsted, New York, 1994.
21. B. W. Silverman. Density Estimation for Statistics and Data Analysis, Chapman and Hall, London, 1986.
22. S. L. Beal and L. B. Sheiner. Heteroscedastic nonlinear regression. Technometrics 30:327- 338 (1988).
23. A. E. Gelfand and A. F. M. Smith. Sampling-based approaches to calculating marginal densities. J. Am. Stat. Assoc. 85:398-409 (1990).
24. A. F. M. Smith and G. O. Roberts. Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods (with discussion). J. Roy. Stat. Soc. A 55:3- 23 (1993).
25. J. Wakefield, A. F. M. Smith, A. Racine-Poon, and A. Gelfand. Bayesian analysis of linear and nonlinear population models. Appl. Statist. 43:201-222 (1994).
26. G. L. Rosner and P. Müller. Pharmacodynamic analysis of hematologic profiles. J. Pharmacokin. Biopharm. 22:499-524 (1994).
27. J. Geweke. Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. In J. O. Berger, J. M. Bernardo, A. P. Dawid, and A. F. M. Smith (eds.), Bayesian Statistics 4, University Press, Oxford, UK, 1992, pp. 169-194.
28. S. R. Searle, G. Casella, and C. E. McCulloch. Variance Components, Wiley, New York, 1992.
29. L. B. Sheiner. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods. Drug Metab. Rev. 15:153-171 (1984).
30. J. L. Steimer, A. Mallet, J. L. Golmard, and J. F. Boisvieux. Alternative approaches to estimation of population pharmacoknetic parameters: Comparison with the nonlinear mixed effect model. Drug Metab. Rev. 15:265-292 (1984).
31. A. Racine-Poon. A Bayesian approach to nonlinear random effects models. Biometrics 41:1015-1023 (1985).
32. E. F. Vonesh and R. L. Carter. Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics 48:1-17 (1992).
33. M. Lindstrom and D. Bates. Nonlinear mixed effects models for repeated measures data. Biometrics 46:673-687 (1990).
34. D. Z. D'Argenio and D. Katz. Discrete approximation of multivariate densities with application to Bayesian estimation. Comput. Statist. Data Anal. 2:27-36 (1984).
35. A. Schumitzky. Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput. 45:141-157 (1991).
36. G. Casella and E. I. George. Explaining the Gibbs sampler. Am. Statist. 46:167-174 (1992).
37. W. K. Hastings. Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57:97-109 (1970).
38. B. D. Ripley. Stochastic Simulation. Wiley, New York, 1987.
39. L. Tierney. Markov chains for exploring posterior distributions (with discussion). Ann. Statist. 22:1701-1762 (1994).
40. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetic pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511-528 (1992).
41. J. Wade, S. L. Beal, and N. C. Sambol. Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J. Pharmacokin. Biopharm. 22:165-177 (1994).
42. C. E. Antoniak. Mixtures of Dirichlet processes with applications to nonparametric problems. Ann. Statist. 2:1152-1174 (1974).
43. M. Davidian and D. M. Giltinan. Some simple methods for estimating intraindividual variability in nonlinear mixed effects models. Biometrics 49:59-73 (1993).
44. G. A. F. Seber. Multivariate Observations, Wiley, New York, 1984.